[go: up one dir, main page]

WO2002017934A1 - Natural, non-allergenic, immune system stimulant - Google Patents

Natural, non-allergenic, immune system stimulant Download PDF

Info

Publication number
WO2002017934A1
WO2002017934A1 PCT/US2000/024428 US0024428W WO0217934A1 WO 2002017934 A1 WO2002017934 A1 WO 2002017934A1 US 0024428 W US0024428 W US 0024428W WO 0217934 A1 WO0217934 A1 WO 0217934A1
Authority
WO
WIPO (PCT)
Prior art keywords
immune system
weight
system stimulator
mixture
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/024428
Other languages
French (fr)
Inventor
Paul Yau Sun Lam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASIA CAPITAL GROUP A BRITISH VIRGIN ISLANDS Corp % CHINESE HERBAL USA Inc
Original Assignee
ASIA CAPITAL GROUP A BRITISH VIRGIN ISLANDS Corp % CHINESE HERBAL USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASIA CAPITAL GROUP A BRITISH VIRGIN ISLANDS Corp % CHINESE HERBAL USA Inc filed Critical ASIA CAPITAL GROUP A BRITISH VIRGIN ISLANDS Corp % CHINESE HERBAL USA Inc
Priority to AU2000271165A priority Critical patent/AU2000271165A1/en
Priority to PCT/US2000/024428 priority patent/WO2002017934A1/en
Priority to US09/885,089 priority patent/US6468541B2/en
Priority to AU2001288236A priority patent/AU2001288236A1/en
Priority to PCT/US2001/024693 priority patent/WO2002018015A1/en
Publication of WO2002017934A1 publication Critical patent/WO2002017934A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/066Clavicipitaceae
    • A61K36/068Cordyceps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965Asparagus, e.g. garden asparagus or asparagus fern

Definitions

  • This invention relates to herbal dietary supplements. More particularly this invention relates to supplements which will stimulate the immune system without producing an allergic response.
  • Herbal supplements unlike medicines are not effective instantaneously but must be taken over long periods of time in order be effective. In other word, it takes time to create an effect in humans.
  • Herbal supplements unlike medicines are not effective instantaneously but must be taken over long periods of time in order be effective. In other word, it takes time to create an effect in humans.
  • This invention is a mixture of five natural herbs.
  • This invention comprises: 5- 80% by weight Hericium, 5-40% by weight Radix Astragali, 5-40% by weight Cordyceps Sinensis, 1-40 % by weight Radix Glycyrrhizae and 5-40% by weight Dioscoreae Oppositae.
  • the powders are size 80 i.e. the powders will pass through a sieve with 80 holes. This is a Chinese standard used in measuring herbal powder.
  • the mixture can be administered in any acceptable form such as in capsules, pressed into tablets, and made into gel caps.
  • Gel caps are a recent development in which a powder is placed in suspension in a fluid and then is encapsulated with a gel.
  • the preferred dosage is 100mg of the invention, twice a day, 100 mg. at breakfast and 100 mg. before bed.
  • lymphyocytes in mini tubes for varying periods in the presence or absence of the invention. 5. Incubate the lymphocytes with 4 serial ten fold dilutions of the invention from 0.1 to 100 ⁇ g/ml
  • l ⁇ L is the standard abbreviation for interleukin.
  • the results showed an impressive production of IL1 beta without an increase in 1 L4. Such production would be helpful during periods of needed immune response, i.e. during a cold or infection.
  • This invention comprises the following mixture. All ingredients are naturally occurring herbs.
  • PBMC peripheral blood mononuclear cells
  • PBMC Isolation Peripheral blood from six healthy volunteers was collected and the PBMC were isolated over a density gradient via centrifugation. The cells were re-suspended in RPMI-1640 containing 10% fetal bovine serum and supplemented with 0.1% of a 50 mg/ml gentamicin solution (Gibco BRL, Grand Island Iowa). PBMC concentration was adjusted to 2 x 106 viable cells/ml after estimation of viability by trypan blue exclusion assay. Viability was consistently greater that 96%.
  • PBMC Culture of PBMC with Herbal Products. Five hundred ml of a 1.0 x 106 cell suspension were cultured with equal volume of the Product treatments at 37°C with 5% C0 2 in 48-well plates. PBMCs were exposed to a final concentration of 100, 10, 1 , 0.1 mg/ml of product. In addition, each product treatment was incubated in the presence of PHA at 10 mg/ml. Culture supernatant fractions were harvested after 72 h and were stored at -20°C until analysis by enzyme linked immunoassay (ELISA).
  • ELISA enzyme linked immunoassay
  • ELISA Analysis of Cytokines Levels of IL1 , IL4, and gamma interferon (IFN) were measured in supernatants from 1.0 x 106 cells/ml stimulated with Product in the presence or absence of PHA.
  • IFN gamma interferon
  • a High Sensitivity Quantikine Human IL4 ELISA kit was used with a detection limit of 0.25 pg/ml (R&D Systems, Minneapolis, MN). Standard ELISA kits were use to quantitate IL1 and IFN (R&D Systems, Minneapolis, MN) with detection limits of 3.9 and 31.2 pg/ml respectively.
  • Results showed an increase of IL1 beta of between 6 and 11 times without any increase in IL4.
  • this product stimulates the human immune system without stimulating IL4, a precursor to allergies in the human body.
  • This testing was conducted by M. Eric Gershwin M.D., The Jack and Donald Chia Professor of Medicine, Chief, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A mixture of 5-80 % by weight Hericium, 5-40 % by weight Radix Astragali, 5-40 % by weight Cordyceps Sinensis, 1-40 % by weight Radix Glycyrrhizae and 5-40 % by weight Dioscoreae Oppositae. Testing shows that this mixture produces an increase in IL1 beta without an increase in 1L4.

Description

Natural. Non-Allerαenic. Immune System Stimulant
Technical Field
This invention relates to herbal dietary supplements. More particularly this invention relates to supplements which will stimulate the immune system without producing an allergic response.
Background Art
Recently, evidence has been accumulating that herbal supplements, taken regularly, may have beneficial effects. Herbal supplements, unlike medicines are not effective instantaneously but must be taken over long periods of time in order be effective. In other word, it takes time to create an effect in humans. There are many products on the market that claim to stimulate the immune system but the research behind such products seems to be borderline at best. See article on Functional food to be published in California Agriculture 2000, probably in November 2000 issue. Stimulating the immune system is a perfect application for herbal supplements because the immune system can be improved gradually. An improved immune system can be beneficial in fighting all kinds of illnesses from the common cold to deadly cancers.
Unfortunately, many herbal supplements can create an allergic response in humans. What is needed is a dietary supplement or herbal supplement that can stimulate the human immune system without allergic response. It is also important that this product have been properly tested for efficacy. Development of an herbal supplement which can stimulate the immune system without producing an allergic response represents a great improvement in the field of medicine and satisfies a long felt need of medical practitioners and their patients. Disclosure of Invention
This invention is a mixture of five natural herbs. This invention comprises: 5- 80% by weight Hericium, 5-40% by weight Radix Astragali, 5-40% by weight Cordyceps Sinensis, 1-40 % by weight Radix Glycyrrhizae and 5-40% by weight Dioscoreae Oppositae. Preferably the powders are size 80 i.e. the powders will pass through a sieve with 80 holes. This is a Chinese standard used in measuring herbal powder.
The mixture can be administered in any acceptable form such as in capsules, pressed into tablets, and made into gel caps. Gel caps are a recent development in which a powder is placed in suspension in a fluid and then is encapsulated with a gel. The preferred dosage is 100mg of the invention, twice a day, 100 mg. at breakfast and 100 mg. before bed.
This invention was tested by the following procedure at the Department of Clinical Immunology at the University of California at Davis:
I. Collect blood.
2. Isolate white cells.
3. Isolate lymphocytes
4. Incubate lymphyocytes in mini tubes for varying periods in the presence or absence of the invention. 5. Incubate the lymphocytes with 4 serial ten fold dilutions of the invention from 0.1 to 100 μg/ml
6. Repeat the same experiments in the presence or absence of phytohemagglutinin (PHA), a known stimulator of cells
7. Collect the culture supernatants (i.e. the fluid above the lymphocytes). 8. Using known standards and a reference curve assay supernatants for IL11 beta and for IL4.
l\L is the standard abbreviation for interleukin. The results showed an impressive production of IL1 beta without an increase in 1 L4. Such production would be helpful during periods of needed immune response, i.e. during a cold or infection.
An appreciation of the other aims and objectives of the present invention and a more complete and comprehensive understanding of it may be achieved by studying the following description of the best mode of carrying out the invention.
Best Mode for Carrying Out Invention
This invention comprises the following mixture. All ingredients are naturally occurring herbs.
Latin Name Weight %
Hericium 5 - 80
Radix Astragali 5 - 40
Cordyceps Sinensis 5 - 40
Radix Glycyrrhizae 1 - 40
Dioscoreae Oppositae 5 - 40
Example: In Vitro Analysis of Herbal Product
Treatment Preparation. Ten mg of herbal product was suspended in 1 ml RPMl2-1640 with 10% heat inactivated fetal bovine serum (media). The suspension was shaken vigorously on a vortex mixer. The insoluble components were quickly pelleted and the remaining suspension filtered twice: first through a 0.45 micron syringe filter followed by a 0.2 micron syringe filter. This filtrate was used as the stock (approx. 10 mg/ml) from which dilutions were made for the
This is a neutral, buffered, solution containing nutrients and special salts, which is designed for growing cells. RPMI stands for Roswell Park Memorial Institute. incubations with peripheral blood mononuclear cells (PBMC). The stock solution was diluted in media prior to treatment with PBMC.
PBMC Isolation. Peripheral blood from six healthy volunteers was collected and the PBMC were isolated over a density gradient via centrifugation. The cells were re-suspended in RPMI-1640 containing 10% fetal bovine serum and supplemented with 0.1% of a 50 mg/ml gentamicin solution (Gibco BRL, Grand Island Nebraska). PBMC concentration was adjusted to 2 x 106 viable cells/ml after estimation of viability by trypan blue exclusion assay. Viability was consistently greater that 96%.
Culture of PBMC with Herbal Products. Five hundred ml of a 1.0 x 106 cell suspension were cultured with equal volume of the Product treatments at 37°C with 5% C02 in 48-well plates. PBMCs were exposed to a final concentration of 100, 10, 1 , 0.1 mg/ml of product. In addition, each product treatment was incubated in the presence of PHA at 10 mg/ml. Culture supernatant fractions were harvested after 72 h and were stored at -20°C until analysis by enzyme linked immunoassay (ELISA).
ELISA Analysis of Cytokines. Levels of IL1 , IL4, and gamma interferon (IFN) were measured in supernatants from 1.0 x 106 cells/ml stimulated with Product in the presence or absence of PHA. For quantitation of secretory IL4, a High Sensitivity Quantikine Human IL4 ELISA kit was used with a detection limit of 0.25 pg/ml (R&D Systems, Minneapolis, MN). Standard ELISA kits were use to quantitate IL1 and IFN (R&D Systems, Minneapolis, MN) with detection limits of 3.9 and 31.2 pg/ml respectively.
Results showed an increase of IL1 beta of between 6 and 11 times without any increase in IL4. In other words this product stimulates the human immune system without stimulating IL4, a precursor to allergies in the human body. This testing was conducted by M. Eric Gershwin M.D., The Jack and Donald Chia Professor of Medicine, Chief, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis.
This invention has been described with reference to a particular embodiment. However, it should be obvious to those skilled in the art to which this invention pertains that other modifications and enhancements can be made without departing from the spirit and scope of the claims that follow.

Claims

Claims
1. An immune system stimulator comprising 5-80% by weight Hericium, 5-40% by weight Radix Astragali, 5-40% by weight Cordyceps Sinensis, 1-40 % by weight Radix Glycyrrhizae and 5-40% by weight Dioscoreae Oppositae.
' 5 2. An immune system stimulator as claimed in claim 1 in which all ingredients are powdered.
3. An immune system stimulator containing a biologically effective amount of the immune system stimulator claimed in claim 1.
10
4. An immune system stimulator as claimed in claim 3 in which said biologically effective amount is 100 mg.
5. An immune system stimulator as claimed in either of claim 1 , 2 or 4 in which 15 said ingredients are incorporated into a pill.
6. An immune system stimulator as claimed in either of claim 1 , 2 or 4 in which said ingredients are contained in a capsule.
20 7. An immune system stimulator as claimed in either of claim 1 , 2 or 4 in which said ingredients are contained in a gel cap.
8. A method of making an immune system stimulator comprising the steps of: a. obtaining powdered Hericium, Radix Astragali, Cordyceps Sinensis, 25 Radix Glycyrrhizae and Dioscoreae Oppositae; and b. mixing 5-80% by weight Hericium, 5-40% by weight Radix Astragali, 5- 40% by weight Cordyceps Sinensis, 1-40 % by weight Radix Glycyrrhizae and 5-40% by weight Dioscoreae Oppositae together.
9. A method of making an immune system stimulator as claimed in claim 8 further comprising the step of forming said mixture into a pill.
10. A method of making an immune system stimulator as claimed in claim 9 in which said pill contains 100 mg. of said mixture.
11. A method of making an immune system stimulator as claimed in claim 8 further comprising the step of incorporating said mixture within a capsule.
12. A method of making an immune system stimulator as claimed in claim 9 in which said capsule contains 100 mg. of said mixture.
13. A method of making an immune system stimulator as claimed in claim 8 further comprising the step of incorporating said mixture within a gel cap.
14. A method of making an immune system stimulator as claimed in claim 9 in which said gel cap contains 100 mg. of said mixture.
PCT/US2000/024428 2000-08-31 2000-08-31 Natural, non-allergenic, immune system stimulant Ceased WO2002017934A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2000271165A AU2000271165A1 (en) 2000-08-31 2000-08-31 Natural, non-allergenic, immune system stimulant
PCT/US2000/024428 WO2002017934A1 (en) 2000-08-31 2000-08-31 Natural, non-allergenic, immune system stimulant
US09/885,089 US6468541B2 (en) 2000-08-31 2001-06-21 Natural, non-allergenic, immune system stimulant
AU2001288236A AU2001288236A1 (en) 2000-08-31 2001-08-08 Natural, non-allergenic, immune system stimulant
PCT/US2001/024693 WO2002018015A1 (en) 2000-08-31 2001-08-08 Natural, non-allergenic, immune system stimulant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/024428 WO2002017934A1 (en) 2000-08-31 2000-08-31 Natural, non-allergenic, immune system stimulant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/885,089 Continuation-In-Part US6468541B2 (en) 2000-08-31 2001-06-21 Natural, non-allergenic, immune system stimulant

Publications (1)

Publication Number Publication Date
WO2002017934A1 true WO2002017934A1 (en) 2002-03-07

Family

ID=21741748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024428 Ceased WO2002017934A1 (en) 2000-08-31 2000-08-31 Natural, non-allergenic, immune system stimulant

Country Status (2)

Country Link
AU (1) AU2000271165A1 (en)
WO (1) WO2002017934A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106093240A (en) * 2016-06-07 2016-11-09 山西大学 A kind of fast-growing Radix Astragali and the discrimination method of the wild Radix Astragali

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHUNG-KUO CHUNG HSI I CHIEH HO TSA CHIH, vol. 14, no. 7, July 1994 (1994-07-01), pages 427 - 428 *
DATABASE CAPLUS ON STN LU ET AL.: "Effect of zi gui decoction on immune function in 60Co.gamma-ray irradiated mice", XP002933877 *
DATABASE MEDLINE ON STN LIN ET AL.: "Inhibition of activated human mesangial cell proliferation by the natural product of cordyceps sinensis (H1-A): An implication for treatment of mesangial nephropathy", XP002933876 *
DATABASE MEDLINE ON STN XU ET AL.: "Immunomodulatory function of polysaccharide of hericium erinaceus", XP002933878 *
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 133, no. 1, January 1999 (1999-01-01), pages 55 - 63 *
ZHONGHUA FANGSHE YIXUE YU FANGHU ZAZHI, vol. 15, no. 1, 1995, pages 17 - 19 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106093240A (en) * 2016-06-07 2016-11-09 山西大学 A kind of fast-growing Radix Astragali and the discrimination method of the wild Radix Astragali

Also Published As

Publication number Publication date
AU2000271165A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
US7923044B2 (en) Composition for high-ORAC value dietary supplement
US5744187A (en) Nutritional powder composition
US6030622A (en) Herbal extract composition and method with immune-boosting capability
WO2003068145A2 (en) Herbal immune system stimulant
Wicks et al. Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial
RU2668126C2 (en) Composition containing combination of elderberry extraction and lactobacillus rhamnosus strain
CN106729280A (en) A kind of composition containing phosphatidylserine and its preparation method and application
US20110052644A1 (en) Composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response
CN104957610A (en) Plant enzyme and preparation method and use thereof
KR20150070515A (en) Composition comprising the extract of complex herbs as an active ingredient for preventing and treating allergy
CN104799286B (en) Composition for improving immunity and preparation method of composition
Jung et al. Immunomodulatory effects of supercritical CO 2 extracted oils from Portulaca oleracea and Perilla frutescens (PPCE) in healthy individuals: a randomized double-blind clinical trial
CN101015618A (en) Health-care wine with sleeping improving and beauty functions and its preparing process
Sharma et al. Adaptogens: new age healing gems for physical wellbeing
CN101810679A (en) Polyunsaturated fatty acid soft capsule and preparation method thereof
CN102630939B (en) Health-care food for treating AIDS (acquired immunodeficiency syndromes) by increasing immunity through dietary therapy and preparation method thereof
US20060159725A1 (en) Herbal compositions
CN109363169A (en) A kind of health-care food composition improved the immunity of the human body and its application
WO2002017934A1 (en) Natural, non-allergenic, immune system stimulant
US6468541B2 (en) Natural, non-allergenic, immune system stimulant
CN106619694A (en) Uses of inulin and common yam rhizome polysaccharide composition in preparation of health food having intestinal flora regulating effect
CN103463253B (en) Fungus medicament for preventing postoperative cancer recurrence and production method thereof
CN1911329B (en) Traditional Chinese medicine composition for preventing and/or adjuvant therapy of malignant tumor
CN107874255A (en) A kind of ginseng is base source health food for relieving physical fatigue and preparation method thereof
CN106359612A (en) Edible selenium-enriched food for old people and preparation method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP